Proficiency of Clinical Laboratories in and near Monterrey, Mexico, To Detect Vancomycin-Resistant Enterococci
1999

Detecting Vancomycin-Resistant Enterococci in Monterrey, Mexico

Sample size: 8 publication Evidence: moderate

Author Information

Author(s): L. Clifford McDonald, Luis R. Garza, William R. Jarvis

Primary Institution: Centers for Disease Control and Prevention

Hypothesis

Can clinical laboratories in Monterrey, Mexico, effectively detect vancomycin-resistant enterococci (VRE)?

Conclusion

The study found that while laboratories can reliably detect high-level vancomycin resistance, many struggle with low-level resistance.

Supporting Evidence

  • VRE infections have increased in the U.S. from 27% to 44% between 1989 and 1995.
  • Laboratories in Monterrey had difficulty detecting low-level vancomycin resistance.
  • Only two laboratories reported an antimicrobial use control program.
  • Errors in vancomycin susceptibility testing were noted, with 23% of results being erroneous.

Takeaway

This study looked at how well hospitals in Monterrey can find a type of bacteria that is hard to treat. They found that while they can find the really resistant ones, they often miss the ones that are only a little resistant.

Methodology

A laboratory survey was conducted where eight hospitals tested five strains of enterococci for vancomycin resistance using their routine methods.

Potential Biases

Some errors may have been caused by inadequately skilled personnel and outdated testing methods.

Limitations

The study did not collect information on the software versions used in automated susceptibility test systems.

Participant Demographics

The eight laboratories serviced hospitals with a median bed count of 148, including neonatal, pediatric, and adult intensive care units.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication